Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eikon Therapeutics, Inc. - Common Stock (NQ:EIKN)

10.14 +0.41 (+4.27%)
Streaming Delayed Price Updated: 11:16 AM EDT, Aug 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,846
Open 9.770
Bid (Size) 10.04 (100)
Ask (Size) 10.25 (200)
Prev. Close 9.730
Today's Range 9.660 - 10.15
52wk Range 7.900 - 17.40
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
Experienced Merck researcher will expand the Board’s drug discovery expertise 
From Eikon Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-32.4%
-32.4%
1 Month
-2.8%
-2.8%
3 Month
+2.0%
+2.0%
6 Month
-30.3%
-30.3%
1 Year
-32.4%
-32.4%

More News

Read More
News headline image
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics to Join the Russell 3000® Index
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering

Frequently Asked Questions

Is Eikon Therapeutics, Inc. - Common Stock publicly traded?
Yes, Eikon Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Eikon Therapeutics, Inc. - Common Stock trade on?
Eikon Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Eikon Therapeutics, Inc. - Common Stock?
The ticker symbol for Eikon Therapeutics, Inc. - Common Stock is EIKN on the Nasdaq Stock Market
What is the current price of Eikon Therapeutics, Inc. - Common Stock?
The current price of Eikon Therapeutics, Inc. - Common Stock is 10.14
When was Eikon Therapeutics, Inc. - Common Stock last traded?
The last trade of Eikon Therapeutics, Inc. - Common Stock was at 08/11/26 11:16 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.